New England Journal of Medicine Review Time: Time to First Decision and Publication

The New England Journal of Medicine is the most cited general medical journal in the world. The 2024 JIF is 78.5 (JCR 2024), ranked 2nd out of 332 general medicine journals. NEJM receives around 5,000-6,000 original research submissions per year and publishes 2-4 original articles per weekly issue.

The result: most papers never make it past the editorial team, and the review process is built to sort quickly.

Timeline at a glance

How NEJM's editorial system works

NEJM uses a team of professional editors (MDs and PhDs with deep clinical and research expertise) who review all submissions internally before any paper goes to external reviewers. This differs from most journals, where a single associate editor makes the desk decision.

When you submit, your paper is initially assigned to one of NEJM's deputy or senior editors. They read the paper and make an independent assessment. If the editor thinks the paper might be interesting, it goes to the full editorial team for brief discussion. Most papers don't make it to that discussion.

This internal editorial system is fast and rigorous. NEJM's editors have seen tens of thousands of clinical submissions and know quickly whether a result is clinically important, whether the methods are sound, and whether the finding adds something meaningful to what clinicians already know.

Desk rejection at NEJM

The desk rejection rate is approximately 80-85% of original research submissions. What leads to desk rejection:

Not for a general medical audience. NEJM's readership spans all clinical specialties. A highly specialized mechanistic study at the molecular level, however excellent, may not be appropriate for a journal that needs content relevant across internal medicine, surgery, pediatrics, and oncology.

Results that don't change practice. NEJM editors think explicitly about whether a paper's findings should change what clinicians do. Studies confirming what's already known typically won't make it through.

Small sample size for the claim. Underpowered studies, unrepresentative samples, or trials without statistical confidence to support clinical recommendations get rejected fast.

Methods that can't support the conclusions. Observational studies making causal claims, meta-analyses with high heterogeneity, or clinical trials with significant protocol violations rarely survive the desk.

What makes it through to external review

Papers reaching external review at NEJM tend to share common features:

• Large, well-designed randomized controlled trials with clinically meaningful outcomes
• Major epidemiological studies with a definitive answer to an important question
• First-in-human or early-phase clinical results for high-potential therapies
• Population-level observational studies with robust methods and a clear public health implication

The standard: does this paper represent information that a thoughtful clinician should know to practice better medicine?

External peer review

Papers passing internal editorial review go to 2-3 external reviewers: leading clinicians, trialists, epidemiologists, and biostatisticians. NEJM asks reviewers to turn reports around in 2-3 weeks. Given the prestige of reviewing for NEJM, reviewers tend to comply.

Reviewer reports focus on clinical importance and novelty, methods validity, generalizability, and whether conclusions are appropriately calibrated to the evidence. Reviewers also flag conflicts of interest, data integrity concerns, and human subjects compliance.

Expedited review

NEJM has a formal process for expedited review of urgent clinical findings: disease outbreaks, findings with immediate clinical safety implications, major trial results. If your paper qualifies, request expedited review in your cover letter with a justification. During COVID-19, NEJM published papers within days of submission for the most critical clinical findings. Under normal circumstances, expedited review still runs 2-4 weeks total.

Revision and post-acceptance

A NEJM revision invitation is a strong signal of acceptance interest. Editors rarely invite revisions for papers they plan to reject. Revisions typically focus on a short list: addressing reviewer concerns about methods, adding subgroup analyses, clarifying limitations, or calibrating claims to evidence.

After acceptance, NEJM's production process puts papers online within 2-3 weeks. Issues publish weekly on Thursdays; papers go online ahead of print immediately after final production.

Comparison with peer journals

JAMA (JIF 63.1): Similar stature, slightly more accessible for specialty clinical research. Comparable timeline.

The Lancet (JIF 54.5): Strong international focus, particularly global health. Similar timeline.

BMJ (JIF 24.4): Faster review (3-6 weeks), more accessible, strong on public health and clinical guidelines. Good alternative when NEJM bar isn't met.

Annals of Internal Medicine (JIF 19.6): Faster, accessible for high-quality clinical research. Good next-tier target after NEJM rejection.

For the full journal overview, see the New England Journal of Medicine journal page. Our manuscript review service covers methods rigor and clinical significance framing for top-tier medical journal submissions.

Impact factor source: Clarivate Journal Citation Reports, JCR 2024.